Advertisement

Selection and Utilization of Monoclonal Antibody Defined Melanoma Associated Antigens for Immunoscintigraphy in Patients with Melanoma

  • S. Ferrone
  • M. Temponi
  • D. Gargiulo
  • G. A. Scassellati
  • R. Cavaliere
  • P. G. Natali
Part of the NATO ASI Series book series (NSSA, volume 152)

Abstract

Analysis of human melanoma cells with murine monoclonal antibodies has identified a number of antigens which are associated with the malignant transformation of melanocytes (for review, see 1,2). These antigens are referred to as melanoma associated antigens (MAA). Most of them, if not all of them, are detectable in melanocytes which are cultured in-vitro and are likely to be differentiation antigens.

Keywords

Melanoma Cell Melanoma Cell Line Human Melanoma Tumor Associate Antigen Human Melanoma Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    K. O. Lloyd, Human tumor antigens detection and characterization with monoclonal antibodies, In: “Basic and Clinical Tumor Immunology,” R.B. Herberman, ed., Martinus Nijhoff Publishers, Boston, USA (1983).Google Scholar
  2. 2.
    P. G. Natali, A. Aguzzi,F. Veglia, K. Imai, R.S. Burlage, P. Giacomini, and S. Ferrone, The impact of monoclonal antibodies on the study of human malignant melanoma, J. Cutan. Pathol. 10:514 (1983).PubMedCrossRefGoogle Scholar
  3. 3.
    D. J. Ruiter, G.M. Dingjam, P.M. Steijlen, M. van Beveren-Hooyer, C.B. De Graaf-Reitsma, W. Bergman, G.N.P. van Muijen, and S.O. Warnaar, Monoclonal antibodies selected to discriminate between malignant melanomas and nevocellular nevi, J. Invest. Dermat. 85:4 (1985).CrossRefGoogle Scholar
  4. 4.
    E. B. Brocker, L. Suter, J. Bruggen, D.J. Ruiter, E. Macher, and C. Sorg, Phenotypic dynamics of tumor progression in human malignant melanoma, Int. J. Cancer 36:29 (1985).PubMedCrossRefGoogle Scholar
  5. 5.
    P. G. Natali, R. Cavaliere, A. Bigotti, and S. Ferrone, An IFN-γ inducible human melanoma associated antigen with preferential distribution in metastases, to be submitted 1987.Google Scholar
  6. 6.
    S. M. Larson, J.A. Carrasquillo, K.A. Krohn, J.P. Brown, R.W. McGuffin, J.M. Ferenes, M.M. Graham, L.D. Hill, P.L. Beaumier, K.E. Hellstrom, and I. Hellstrom, Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy, J. Clin. Invest. 72:2101 (1983).PubMedCrossRefGoogle Scholar
  7. 7.
    A. G. Siccardi, G.L. Buraggi, L. Callegaro, G. Mariani, P.G. Natali, A. Abbati, M. Bestagno, V. Caputo, L. Mansi, R. Masi, G. Paganelli, P. Riva, M. Salvatore, M. Sanguineti, E.L. Troncone, G.L. Turco, G.A. Scassellati, and S. Ferrone, Multicenter study of immunoscintigraphy with radiolabeled monoclonal antibodies in patients with melanoma, Cancer Res. 46:4817 (1986).PubMedGoogle Scholar
  8. 8.
    P. Casellas, J.P. Brown, O. Gros, P. Gros, I. Hellstrom, F. K. Jansen, P. Poncelet, R. Roncucci, H. Vidal, and K.E. Hellstrom, Human melanoma cells can be killed in vitro by an immunotoxin specific for melanoma-associated antigen p97, Int. J. Cancer 30:437 (1982).PubMedCrossRefGoogle Scholar
  9. 9.
    T. F. Bumol, Q.C. Wang, R.A. Reisfeld, and N. O. Kaplan, Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth. Proc. Natl. Acad. Sci. USA 80:529 (1983).PubMedCrossRefGoogle Scholar
  10. 10.
    K. Imai, T. Nakanishi, T. Noguchi, S. Yachi, and S. Ferrone, Selective in vitro toxicity of purothionin conjugated to the monoclonal antibody 225.28S to a human high-molecular-weight melanoma-associated antigen, Cancer Immunol. Immunother. 15:206 (1983).PubMedCrossRefGoogle Scholar
  11. 11.
    M. Matsui, T. Nakanishi, T. Noguchi, K. Imai, A. Yachi, and S. Ferrone, Suppression of human melanoma growth in nude mice injected with anti high-molecular weight melanoma-associated antigen monoclonal antibody 225.28S conjugated to purothionin, Jpn. J. Cancer Res. (Gann) 76:119 (1985).Google Scholar
  12. 12.
    W. G. Dippold, A. Knuth, and K.H. Meyer sum Buschenfelde, Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody, Cancer Res. 44:806 (1984).PubMedGoogle Scholar
  13. 13.
    D. A. Cheresh, C.J. Honsik, L.K. Staffileno, G. Jung, and R.A. Reisfeld, Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis, Proc. Natl. Acad. Sci. USA 82:5155 (1985).PubMedCrossRefGoogle Scholar
  14. 14.
    A. N. Houghton, D. Mintzer, C. Cordon-Cardo, S. Welt, B. Fliegel, S. Vadhan, E. Carswell, M.R. Melamed, H.F. Oettgen, and L.J. Old, Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma, Proc. Natl. Acad. Sci. USA 82:1242 (1985).PubMedCrossRefGoogle Scholar
  15. 15.
    I. Hellstrom, V. Brankovan, and K.E. Hellstrom, Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside, Proc. Natl. Acad. Sci. USA 82:1499 (1985).PubMedCrossRefGoogle Scholar
  16. 16.
    R. F. Irie and D.L. Morton, Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2, Proc. Natl. Acad. Sci. USA 83:8694 (1986).PubMedCrossRefGoogle Scholar
  17. 17.
    W. J. Rettig, F.X. Real, B.A. Spengler, J.L. Biedler, and L.J. Old, Human melanoma proteoglycan:Expression in hybrids controlled by intrinsic and extrinsic signals, Science 231:1281 (1986).PubMedCrossRefGoogle Scholar
  18. 18.
    H. J. Garrigues, M.W. Lark, S. Lara, I. Hellstrom, K.E. Hellstrom, and T. Wight, The melanoma proteoglycan:restricted expression on microspikes, a specific microdomain of the cell surface, J. Cell Biology 103: 1699 (1986).CrossRefGoogle Scholar
  19. 19.
    J. R. Harper and R.A. Reisfeld, Inhibition of anchorage-independent growth of human melanoma cells by a monoclonal antibody to a chondroitin sulfate proteoglycan, J. Natl. Cancer Inst. 71:259 (1983).PubMedGoogle Scholar
  20. 20.
    T. F. Bumol, L.E. Walker, and R.A. Reisfeld, Biosynthetic studies of proteoglycans in human melanoma cells with a monoclonal antibody to a core glycoprotein of chondroitin sulfate proteoglycans, J. Biol. Chem. 259:12733 (1984)PubMedGoogle Scholar
  21. 21.
    J. E. De Vries, G.K Keizer, A.A. Te Velde, A. Voordouw, D. Ruiter, P. Rumke, H. Spits, and C.G. Figdor, Characterization of melanoma-associated surface antigens involved in the adhesion and motility of human melanoma cells, Int. J. Cancer 38:465 (1986).PubMedCrossRefGoogle Scholar
  22. 22.
    P. G. Natali, K. Imai, B.S. Wilson, A. Bigotti, R. Cavaliere, M.A. Pellegrino, and S. Ferrone, Structural properties and tissue distribution of the antigen recognized by the monoclonal antibody 653.40S to human melanoma cells, J. Natl. Cancer Inst. 67:591 (1981).PubMedGoogle Scholar
  23. 23.
    B. S. Wilson, K. Imai, P.G. Natali, and S. Ferrone, Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies, Int. J. Cancer 28:293 (1981).PubMedCrossRefGoogle Scholar
  24. 24.
    T. F. Bumol and R. A. Reisfeld, Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells, Proc. Natl. Acad. Sci.USA 79:1245 (1982).PubMedCrossRefGoogle Scholar
  25. 25.
    I. Hellstrom, H.J. Garrigues, L. Cabasco, G.H. Mosely, J.P. Brown, and K.E. Hellstrom, Studies of a high molecular weight human melanoma-associated antigen, J. Immunol. 130:1467 (1983).PubMedGoogle Scholar
  26. 26.
    A. H. Ross, G. Cossu, M. Herlyn, J.R. Bell, Z. Steplewski, and H. Koprowski, Isolation and chemical characterization of a melanoma-associated proteoglycan antigen, Arch. Biochem. Biophys. 225:370 (1983).PubMedCrossRefGoogle Scholar
  27. 27.
    B. S. Wilson, G. Ruberto, and S. Ferrone, Immunochemical characterization of a human high molecular weight melanoma-associated antigen identified with monoclonal antibodies, Cancer Immunol. Immunother. 14:196 (1983).PubMedCrossRefGoogle Scholar
  28. 28.
    R. R. S. Kantor, A.P. Albino, A.K. Ng, and S. Ferrone, Biosynthesis and intracellular processing of four human melanoma associated antigens, Cancer Res. 46:5223 (1986).PubMedGoogle Scholar
  29. 29.
    B. S. Wilson, N.E. Kay, K. Imai, and S. Ferrone, Heterogeneity of human melanoma associated antigens defined by monoclonal antibodies and conventional xenoantisera, Cancer Immunol. Immunother. 13:69 (1982).PubMedCrossRefGoogle Scholar
  30. 30.
    A. C. Morgan, Jr., C. Woodhouse, R. Bartholemew, and R. Schroff, Human melanoma-associated antigens:analysis of antigenic heterogeneity by molecular, serologic and flow-cytometric approaches, Molecular Immunology 23:193 (1986).PubMedCrossRefGoogle Scholar
  31. 31.
    M. R. Ziai, L. Imberti, M. R. Nicotra, G. Badaracco, O. Segatto, P.G. Natali, and S. Ferrone, Analysis with monoclonal antibodies of the molecular and cellular heterogeneity of human molecular weight-melanoma associated antigen, Cancer Res. In press, (1987).Google Scholar
  32. 32.
    A. Godal, Ø. Bruland, E. Haug, M. Aas, and Ø. Fodstad, Unexpected expression of the 250 kD melanoma-associated antigen in human sarcoma cells, Br. J. Cancer 53:839 (1986).PubMedCrossRefGoogle Scholar
  33. 33.
    S. -K. Liao, J.W. Smith, P.C. Kwong, P.G. Natali, M. Kusama, C.V. Hamby, and S. Ferrone, Crossreactivity of anti human high molecular weight melanoma-associated antigen (HMW-MAA) monoclonal antibodies with guinea pig melanoma cells, Cancer Res. submitted (1987).Google Scholar
  34. 34.
    P. G. Natali, A. Bigotti, R. Cavaliere, M.R. Nicotra, and S. Ferrone, Phenotyping of lesions of melanocyte origin with monoclonal antibodies to melanoma-associated antigens and to HLA antigens, J. Natl. Cancer Inst. 73:13, 1984.PubMedGoogle Scholar
  35. 35.
    P. Giacomini, F. Veglia, P. Cordiali Fei, T. Rehle, P.G. Natali, and S. Ferrone, Level of a membrane-bound high-molecular-weight melanoma-associated antigen and a cytoplasmic melanoma-associated antigen in surgically removed tissues and sera from patients with melanoma, Cancer Res. 44:1281, 1984.PubMedGoogle Scholar
  36. 36.
    T. Lindmo, E. Boven, F. Cuttitta, J. Fedorko, and P.A. Bunn, Jr., Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess, J. Immunol. Meth. 72:77 (1984).CrossRefGoogle Scholar
  37. 37.
    P. Giacomini, P.G. Natali, and S. Ferrone, Analysis of the interaction between a human high molecular weight melanoma-associated antigen and the monoclonal antibodies to three distinct antigenic determinants, J. Immunol. 135:696, 1985.PubMedGoogle Scholar
  38. 38.
    P. L. Beaumier, D. Neuzil, H.M. Yang, E.A. Noll, R. Kishore, J.F. Eary, K.A. Krohn, W.B. Nelp, K.E. Hellstrom, and I. Hellstrom, Immunoreactivity assay for labeled anti-melanoma monoclonal antibodies, J. Nucl Med. 27:824 (1986).PubMedGoogle Scholar
  39. 39.
    P. G. Natali, R. Cavaliere, A. Bigotti, M.R. Nicotra, C. Russo, A.K. Ng, P. Giacomini, and S. Ferrone, Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions, J. Immunol. 130:1462 (1983).PubMedGoogle Scholar
  40. 40.
    P. G. Natali, A. Bigotti, R. Cavaliere, S.-K. Liao, M. Taniguchi, M. Matsui, and S. Ferrone, Heterogeneous expression of melanoma-associated antigens and HLA antigens by primary and multiple metastatic lesions removed from patients with melanoma, Cancer Res. 45:2883 (1985).PubMedGoogle Scholar
  41. 41.
    M. S. Ernstoff, P. Duray, K. Stenn, and J.M. Kirkwood, Antigenic phenotype of pigment cell lesions:A study of melanoma, its precursor lesions and heterogeneity in metastatic melanoma, J. Invest. Dermat. 84:430 (1985).CrossRefGoogle Scholar
  42. 42.
    C. Cillo, J.-P. Mach, M. Schreyer, and S. Carrel, Antigenic heterogeneity of clones and subclones from human melanoma cell lines demonstrated by a panel of monoclonal antibodies and flow microfluorometry analysis, Int. J. Cancer 34:11 (1984).PubMedCrossRefGoogle Scholar
  43. 43.
    A. Anichini, R. Mortarini, G. Fossati, and G. Parmiani, Phenotypic profile of clones from early cultures of human metastatic melanomas and its modulation by recombinant interferon-γ, Int. J. Cancer 38:505 (1986).PubMedCrossRefGoogle Scholar
  44. 44.
    C. de L. Davies, E.K. Rofstad, and T. Lindmo, Hyperthermia-induced changes in antigen expression on human FME melanoma cells, Cancer Res. 45:4109 (1985).Google Scholar
  45. 45.
    P. Giacomini, A. Aguzzi, S. Pestka, P.B. Fisher, and S. Ferrone, Modulation by recombinant DNA leukocyte (α) and Fibroblast (β) interferons of the expression and shedding of HLA- and tumor-associated antigens by human melanoma cells, J. Immunol. 133:1649 (1984).PubMedGoogle Scholar
  46. 46.
    S. Carrel, A. Schmidt-Kessen, and L. Giuffre, Recombinant interferon-γ can induce the expression of HLA-DR and -DC on DR-negative melanoma cells and enhance the expression of HLA-ABC and tumor associated antigens, Eur. J. Immunol 15:118 (1985).PubMedCrossRefGoogle Scholar
  47. 47.
    P. Giacomini, L. Imberti, A. Aguzzi, P.B.. Fisher, G. Trinchieri, and S. Ferrone, Immunochemical analysis of the modulation of human melanoma-associated antigens by DNA recombinant immune interferon, J. Immunol. 135:2887 (1985).PubMedGoogle Scholar
  48. 48.
    D. Taramelli, G. Fossati, A. Mazzocchi, D. Delia, S. Ferrone, and G. Parmiani, Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions, Cancer Res. 46:433 (1986).PubMedGoogle Scholar
  49. 49.
    H. W. Loms Ziegler-Heitbrock, R. Munker, J. Johnson, I. Petersmann, C. Schmoeckel, and G. Riethmuller, In vitro differentiation of human melanoma cells analyzed with monoclonal antibodies, Cancer Res. 45:1344 (1985).Google Scholar
  50. 50.
    A. H. Ross, M. Herlyn, C.S. Ernst, D. Guerry, J. Bennicelli, B.F.D. Ghrist, B. Atkinson, and H. Koprowski, Immunoassay for melanoma-associated proteoglycan in the sera of patients using monoclonal and polyclonal antibodies, Cancer Res. 44:4642 (1984).PubMedGoogle Scholar
  51. 51.
    J. -P. Mach, F. Buchegger, M. Michel , J. Ritschard, C. Berche, J.-D. Lumbroso, M. Schreyer, C. Girardet, R.S. Accolla, and S. Carrel, Use of radiolabelled monoclonal anti-CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphy, Immunology Today 2:239 (1981).CrossRefGoogle Scholar
  52. 52.
    G. L. Buraggi, L. Callegaro, G. Mariani, A. Turrin, N. Cascinelli, A. Attili, E. Bombardieri, G. Terno, G. Plassio, M. Dovis, N. Mazzuca, P.G. Natali, U. Rosa, and S. Ferrone, Imaging with 131I-labeled monoclonal antibodies to a high molecular weight-melanoma-associated antigen in patients with melanoma:efficacy of whole immunoglobulin and its F(ab′)2 fragments, Cancer Res. 45:3378 (1985).PubMedGoogle Scholar
  53. 53.
    T. Ghose, S. Ferrone, K. Imai, S.T. Novell, S.J. Luner, Jr., R.H. Martin, and A.H. Blair, Imaging of human melanoma xenografts in nude mice with a radiolabelled monoclonal antibody, J. Natl. Cancer Inst. 69:823 (1982).PubMedGoogle Scholar
  54. 54.
    K. M. Hwang, O. Fodstad, R.K. Oldham, and A.C. Morgan, Jr., Radiolocalization of xenografted human malignant melanoma by a monoclonal antibody (9.2.27) to a melanoma-associated antigen in nude mice, Cancer Res. 45:4150 (1985).PubMedGoogle Scholar
  55. 55.
    S. M. Larson, J.A. Carrasquillo, R.W. McGuffin, K.A. Krohn, J.M. Ferens, L.D. Hill, P.L. Beaumier, J.C. Reynolds, K.E. Hellstrom, and I. Hellstrom, Use of I-131 labeled, murine Fab against a high molecular weight antigen of human melanoma:Preliminary experience, Radiology 155:487 (1985).PubMedGoogle Scholar
  56. 56.
    J. L. Murray, M.G. Rosenblum, L. Lamki, H.J. Glenn, Z. Krizan, E.M. Hersh, C.E. Plager, R.M. Bartholomew, M.W. Unger, and D.J. Carlo, Clinical parameters related to optimal tumor localization of indium-111-labelled mouse antimelanoma monoclonal antibody ZME-018, J. Nucl Med. 28:25 (1987).PubMedGoogle Scholar
  57. 57.
    R. W. Schroff, C.S. Woodhouse, K.A. Foon, R.K. Oldham, M.M. Farrell, R.A. Klein, and A.C. Morgan, Jr., Intratumor localization of monoclonal antibody in patients with melanoma treated antibody to a 250,000-dalton melanoma-associated antigen, J. Natl. Cancer Inst. 74:299 (1985).PubMedGoogle Scholar
  58. 58.
    Z. Krizan, J.L. Murray, E.M. Hersh, M.G. Rosenblum, H.J. Glenn, C.R. Gschwind, and D.J. Carlo, Increased labeling of human melanoma cells in vitro using combinations of monoclonal antibodies recognizing separate cell surface antigenic determinants, Cancer Res. 45:4904 (1985).PubMedGoogle Scholar
  59. 59.
    J. -F. Chatal, J.-C. Saccavini, P. Fumoleau, J.-Y. Douillard, C. Curtet, M. Kremer, B. Le Mevel, and H. Koprowski, Immunoscintigraphy of colon carcinoma, J. Nucl. Med. 25:307 (1984).PubMedGoogle Scholar
  60. 60.
    P. J. Fraker and J. C. Speck, Jr., Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril, Biochem. Biophys. Res. Commun. 80:849 (1978).PubMedCrossRefGoogle Scholar
  61. 61.
    T. Lindmo, E. Boven, F. Cuttitta, J. Fedorko, and P.A. Bunn, Jr., Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess, J. Immunol. Methods 72:77 (1984).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • S. Ferrone
    • 1
  • M. Temponi
    • 1
  • D. Gargiulo
    • 1
  • G. A. Scassellati
    • 2
  • R. Cavaliere
    • 3
  • P. G. Natali
    • 4
  1. 1.Department of Microbiology and ImmunologyNew York Medical CollegeValhallaUSA
  2. 2.Research CenterSorin BiomedicaSaluggiaItaly
  3. 3.Department of SurgeryRegina Elena Cancer InstituteRomeItaly
  4. 4.Laboratory of ImmunologyRegina Elena Cancer InstituteRomeItaly

Personalised recommendations